Endo in another below-the-belt acquisition

Share this article:
Endo Pharmaceuticals announced plans to acquire American Medical Systems, a Minnesota maker of pelvic health products and devices.

The $2.9 billion deal is the latest in a string of acquisitions for Chadds Ford, PA-based Endo, a specialty firm best known for its pain portfolio. Endo acquired generics-maker Qualitest in December and urology specialty HealthTronics last July.

American Medical Systems, which makes products for male and female incontinence, erectile dysfunction, prostate disorders, urethral strictures and other pelvic floor conditions including prolapse, reported a 4.4% rise in revenue for 2010 over 2009 to $542.3 million. That made it about a quarter the size of Endo, which reported revenues up 17% to $1.7 billion for 2010 and has forecast 2011 sales of between $2.35 billion and $2.45 billion. The combined company will have around 4,000 employees and revenues of around $3 billion, said Endo.

Endo president and CEO Dave Holveck said in a statement: “Through the acquisition of AMS, we will gain scale in devices and services, and will be positioned as a leading provider of healthcare solutions in the field of pelvic health, with a full spectrum of product offerings ranging from pharmaceuticals to medical devices.”

While Endo's pain portfolio remains its bread and butter, the company has been building a respectable franchise in urology and sexual health, most recently with the FDA approval in December of Fortesta, a topical gel for low testosterone that is being launched with 500 reps – around two-thirds of Endo's pre-merger sales force.  
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...